I think this one is a serious sleeper. Just takes a long term perspective. We have regular good news, occasional surprise profitable quarters, management that knows how to buy and sell promising drug tech and drug tech companies (at a profit), very promising drugs in the pipeline, a strong rising support line for low risk buys and additions (currently at about .80 to .82), marketable shares in ANX that should triple in value later this year (I also have shares in ANX), and two drug companies now footing the bill to move two previously shelved for funding CYTR products along the pipeline at their expense, with rewards for CYTR if and when they pass periodic stages of testing toward FDA approval. CYTR has plenty of cash, survived the 08-09 crash and the recent trial news on main line drugs as been astounding!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.